OrthoPediatrics (NASDAQ:KIDS) Sets New 1-Year High – Here’s Why

OrthoPediatrics Corp. (NASDAQ:KIDS) reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $25.38 and last traded at $25.2860, with a volume of 78942 shares. The stock had previously closed at $24.70.

Wall Street Analysts Forecast Growth

KIDS has been the topic of several research analyst reports. TD Cowen reaffirmed a “buy” rating on shares of OrthoPediatrics in a research report on Monday, June 15th. Canaccord Genuity Group set a $25.00 target price on OrthoPediatrics in a research note on Friday, April 24th. Piper Sandler reaffirmed an “overweight” rating and issued a $25.00 target price (up from $22.00) on shares of OrthoPediatrics in a report on Wednesday, August 5th. Needham & Company LLC raised their price objective on shares of OrthoPediatrics from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Finally, Truist Financial set a $22.00 target price on shares of OrthoPediatrics in a research report on Wednesday, August 5th. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $25.89.

OrthoPediatrics Stock Performance

The firm has a market capitalization of $664.68 million, a price-to-earnings ratio of -15.14 and a beta of 0.98. The firm’s 50-day moving average price is $20.23 and its two-hundred day moving average price is $18.17. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.17 and a current ratio of 4.78.

OrthoPediatrics (NASDAQ:KIDS) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.04. OrthoPediatrics had a negative net margin of 15.72% and a negative return on equity of 8.10%. The firm had revenue of $70.51 million during the quarter, compared to analyst estimates of $68.21 million. Sell-side analysts predict that OrthoPediatrics Corp. will post -1.14 earnings per share for the current year.

Hedge Funds Weigh In On OrthoPediatrics

A number of institutional investors and hedge funds have recently bought and sold shares of KIDS. Russell Investments Group Ltd. lifted its position in shares of OrthoPediatrics by 433.1% during the third quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock worth $26,000 after purchasing an additional 1,139 shares in the last quarter. Legal & General Group Plc bought a new stake in shares of OrthoPediatrics during the second quarter worth $34,000. Northwestern Mutual Wealth Management Co. raised its position in shares of OrthoPediatrics by 5,226.5% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock worth $46,000 after acquiring an additional 2,561 shares during the last quarter. Caption Management LLC acquired a new position in shares of OrthoPediatrics during the third quarter valued at $54,000. Finally, BNP Paribas Financial Markets lifted its stake in shares of OrthoPediatrics by 60.2% during the third quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock valued at $61,000 after acquiring an additional 1,235 shares during the period. Institutional investors and hedge funds own 69.05% of the company’s stock.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.